Zhang Xi-Hao, Cao Man-Qing, Li Xiu-Xiu, Zhang Ti
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
World J Hepatol. 2020 Oct 27;12(10):766-774. doi: 10.4254/wjh.v12.i10.766.
Angiogenesis plays an important role in the occurrence and development of tumors. Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma (HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC.
血管生成在肿瘤的发生和发展中起重要作用。已注册的靶向血管内皮生长因子的酪氨酸激酶抑制剂可减少血管生成。阿帕替尼作为一种酪氨酸激酶抑制剂，能特异性抑制血管内皮生长因子受体2，在包括晚期肝细胞癌（HCC）在内的多种肿瘤中显示出令人鼓舞的抗肿瘤效果。本文旨在综述阿帕替尼在HCC领域的临床研究及应用前景。
